VIP (10mg)

Description

What is VIP?

Vasoactive Intestinal Peptide (VIP) is an endogenous 28‑residue neuropeptide belonging to the secretin/glucagon superfamily. It is widely distributed in the central and peripheral nervous system, GI tract, and immune tissues. VIP has been extensively studied as a potent endogenous anti‑inflammatory mediator and is being investigated pharmaceutically for sarcoidosis, pulmonary arterial hypertension, and chronic‑inflammatory‑response syndromes.

Mechanism of Action

• Activates VPAC1 and VPAC2 G‑protein‑coupled receptors → cAMP elevation
• Shifts macrophage polarization toward M2 anti‑inflammatory phenotype
• Downregulates TNF‑α, IL‑6, iNOS, and enhances IL‑10 production
• Potent pulmonary and systemic vasodilator
• Modulates T‑regulatory cell differentiation

Compound Properties

• Molecular formula: C₁₄₇H₂₃₇N₄₃O₄₃S
• Molecular weight: ~3326.8 g/mol
• CAS: 37221‑79‑7
• Sequence: HSDAVFTDNYTRLRKQMAVKKYLNSILN‑NH₂
• Form: Lyophilized powder
• Unit size: 10 mg / vial
• Source: Solid‑phase peptide synthesis; ≥98% purity by HPLC

Research‑Reference Dosing

Published research‑reference ranges in clinical and preclinical literature:

• Leuchte et al., American Journal of Respiratory and Critical Care Medicine (2008): inhaled aviptadil (synthetic VIP) in pulmonary arterial hypertension.
• Said et al., Annals of the New York Academy of Sciences (2006, 2011): VIP biology and therapeutic development.
• Prasse et al., European Respiratory Journal (2010): inhaled VIP in pulmonary sarcoidosis (Phase II).
• Shulkes & Baldwin: reviews of VIP pharmacology.

Research Findings

• Reduced granuloma burden and inflammatory cytokines in pulmonary sarcoidosis with inhaled VIP (Prasse 2010)
• Improved pulmonary hemodynamics with inhaled aviptadil (Leuchte 2008)
• Emergency‑use investigations in severe COVID‑19 ARDS via aviptadil (Relief Therapeutics) — mixed late‑stage outcomes

Known Side Effects Reported in Research/Trials

• Flushing, hypotension, tachycardia (potent vasodilator)
• Diarrhea and GI motility changes
• Headache
• Bronchoconstriction reported in rare cases with inhaled formulations
• Very short plasma half‑life (~1–2 min) requires continuous infusion or inhalation in clinical use

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.